文献速递认知障碍与痴呆

阿尔茨海默病Tau PET分期的统一视觉判读框架

A Harmonized Visual Reading Framework for Tau PET Staging in Alzheimer Disease.
PubMed 文献 · JAMA Neurol · 2026-09-21

这项前瞻性多中心横断面研究在HEAD队列中开发并验证了跨示踪剂的5类Tau PET视觉判读框架(阴性、低、中、高、非典型)。框架的判读者间和示踪剂间一致性优良,相比监管批准的二分法能识别更多早期Tau阳性个体,且Tau负荷类别与认知、Aβ负荷及血浆p-tau217呈阶梯式关联。

要点

  • 统一5类框架判读者间一致性κ=0.77-0.85,示踪剂间一致性良好至优秀。
  • 相比监管二分法,统一框架在认知未受损者中识别更多Tau阳性(PR最高2.73)。
  • Tau负荷类别与认知、Aβ PET负担和血浆p-tau217呈阶梯式恶化相关。

核心结论

  • 5类统一Tau PET视觉判读框架具有高判读者间和示踪剂间一致性,能检测更多早期Tau病理,且Tau负荷类别与认知和生物标志物阶梯式相关。

研究设计与样本

  • 前瞻性多中心横断面研究,纳入HEAD研究中50至90岁完成多示踪剂Tau PET和认知评估的参与者,来自北美和欧洲9个中心。
  • 共纳入681名参与者,平均年龄69.3(8.4)岁,女性367人(53.9%),涵盖认知未受损至痴呆。
  • Tau PET示踪剂包括18F-MK-6240(n=681)、18F-flortaucipir(n=644)、18F-RO948(n=150)和18F-PI-2620(n=149),所有参与者均接受Aβ PET和MRI。

主要发现

  • 统一5类框架的判读者间一致性κ=0.77-0.85,示踪剂间一致性良好至优秀,18F-MK-6240与18F-flortaucipir间最高(κ=0.88)。
  • 在认知未受损者中,监管二分法识别26/364例Tau阳性,统一18F-flortaucipir识别49/364例(PR=1.89;95%CI 1.31-2.70;P=.001),统一18F-MK-6240识别71/364例(PR=2.73;95%CI 1.95-3.83;P<.001)。
  • 在轻度认知障碍者中,监管二分法识别100/223例,统一18F-flortaucipir识别123/223例(PR=1.23;95%CI 1.12-1.35;P<.001),统一18F-MK-6240识别142/223例(PR=1.42;95%CI 1.27-1.59;P<.001),痴呆阶段两者趋同。
  • Tau负荷类别与认知、Aβ PET负担和血浆p-tau217呈阶梯式恶化,低Tau类别与高Tau类别间分别相差1.4倍、3.2倍和2.5倍。

关键数值与推荐

  • 统一框架将Tau负荷分为5类:阴性、低、中、高、非典型。
  • 判读者间一致性κ=0.77-0.85,示踪剂间一致性最高κ=0.88(18F-MK-6240与18F-flortaucipir)。
  • 认知未受损者中统一框架Tau阳性率高于监管二分法,18F-flortaucipir的PR=1.89(95%CI 1.31-2.70;P=.001),18F-MK-6240的PR=2.73(95%CI 1.95-3.83;P<.001)。
  • 轻度认知障碍者中18F-flortaucipir的PR=1.23(95%CI 1.12-1.35;P<.001),18F-MK-6240的PR=1.42(95%CI 1.27-1.59;P<.001)。

临床怎么用

  • 该框架可用于跨示踪剂的标准化Tau PET诊断分类,有助于识别早期Tau病理和治疗窗口。
  • 统一5类分期可支持临床试验分层,并追踪Tau负荷与认知及生物标志物的阶梯式关联。

局限性

  • 研究为横断面设计,无法评估框架对纵向结局的预测价值。
  • 数据来自HEAD研究参与者,外部推广性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Tau positron emission tomography (PET) can detect and stage Alzheimer disease pathology; however, current binary regulatory-approved visual interpretation focuses on advanced disease, limiting early detection and patient stratification. OBJECTIVE: To develop and validate a harmonized tau PET visual reading framework across radiotracers that stages tau burden into 5 classes: negative, low, moderate, high, and atypical. DESIGN, SETTING, AND PARTICIPANTS: This prospective multicenter cross-sectional study among a cohort with head-to-head tau PET acquisitions was conducted from March 2022 to August 2025 and data analyzed from February to June 2026, with blinded visual reads performed by clinicians. The study was conducted at 9 sites across North America and Europe. Of those individuals enrolled in the HEAD (Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease) study, a proportion of participants aged 50 to 90 years who completed multitracer tau PET (2-4 scans) and cognitive assessments were included, spanning cognitively unimpaired to dementia. EXPOSURES: Tau PET with 18F-MK-6240 (TAUKLARIFY, n = 681), 18F-flortaucipir (Tauvid, n = 644), 18F-RO948 (n = 150), and 18F-PI-2620 (n = 149); all participants underwent amyloid-β (Aβ) PET and magnetic resonance imaging. MAIN OUTCOMES AND MEASURES: The primary outcomes were interrater and intertracer agreement for 5-class tau classification; prevalence ratio (PR) vs the regulatory-approved 18F-flortaucipir framework; and associations with cognition, Aβ burden, and plasma phosphorylated tau 217 (p-tau217). RESULTS: Of 822 individuals enrolled in the HEAD study, 681 participants spanning cognitively unimpaired to dementia were included. Mean (SD) age was 69.3 (8.4) years, and 367 participants (53.9%) were female. The harmonized 5-class framework achieved excellent interrater agreement (κ = 0.77-0.85) and good to excellent intertracer agreement, highest between 18F-MK-6240 and 18F-flortaucipir (κ = 0.88). Compared with the regulatory-approved framework, the harmonized classification identified more tau-positive cognitively unimpaired participants (regulatory-approved binary: 26 of 364 participants; harmonized 18F-flortaucipir: 49 of 364 [PR = 1.89; 95% CI, 1.31-2.70; P = .001]; harmonized 18F-MK-6240: 71 of 364 [PR = 2.73; 95% CI, 1.95-3.83; P < .001]) and those with mild cognitive impairment (regulatory-approved binary: 100 of 223; harmonized 18F-flortaucipir: 123 of 223 [PR = 1.23; 95% CI, 1.12-1.35; P < .001]; harmonized 18F-MK-6240: 142 of 223 [PR = 1.42; 95% CI, 1.27-1.59; P < .001]), with convergence in dementia. Tau burden classes showed stepwise worsening of cognition, Aβ PET burden, and plasma p-tau217, with 1.4-fold, 3.2-fold, and 2.5-fold differences between the low and high tau classes, respectively. CONCLUSIONS AND RELEVANCE: In this prospective multitracer cross-sectional study, a 5-class harmonized tau PET visual reading framework showed high interrater and intertracer agreement and detected more early-stage tau pathology than the regulatory-approved binary approach, with tau burden classes tracking stepwise with cognition and biomarkers. These findings support a standardized, tracer-agnostic framework for diagnostic categorization, therapeutic window identification, and clinical trial stratification.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Ruppert E, Vermeiren MR, Scop Medeiros M, et al. A Harmonized Visual Reading Framework for Tau PET Staging in Alzheimer Disease. JAMA Neurol. 2026. PMID: 42766299. doi:10.1001/jamaneurol.2026.3253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。